Hypertrophic cardiomyopathy(HCM)is the most common inherited cardiomyopathy and is characterized by left ventricular hypertrophy,myocardial hypercontraction,and diastolic dysfunction.Drug treatment options of HCM are limited,including beta blockers,calcium channel blockers.These drugs do not prevent progression of the natural history and are not effective in reducing the incidence of complications.In recent years,increased knowledge of the genetic basis and pathophysiological mechanisms of HCM has led to the development of targeted,potentially disease-modifying therapies.In this article,we systematically describe the drug treatment of this disease based on the latest research progress.
维普
万方数据